Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 11 of 11 results for rucaparib

  1. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)

    Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    17 September 2024
    View recommendations

    Sections for TA1007

  2. Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]

    Awaiting development [GID-TA11219] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]

    Awaiting development [GID-TA11216] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]

    In development [GID-TA10999] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development

  5. Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (TA946)

    Evidence-based recommendations on olaparib (Lynparza) with bevacizumab (Avastin) for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.

    Technology appraisal guidance
    Published
    17 January 2024
    View recommendations

    Sections for TA946

  6. Rucaparib for treating ovarian, fallopian tube or peritoneal cancer that has a BRCA mutation [ID1184]

    Discontinued [GID-TA10168]

    Technology appraisal guidance
    Discontinued

  7. Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764

    Awaiting development [GID-TA11049] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763

    Awaiting development [GID-TA11048] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

    Discontinued [GID-TA10492]

    Technology appraisal guidance
    Discontinued

  10. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

    Discontinued [GID-TA10490]

    Technology appraisal guidance
    Discontinued

  11. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.

    Technology appraisal guidance
    Published
    13 November 2019